Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. National Australia Bank Limited
  6. News
  7. Summary
    NAB   AU000000NAB4


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wall Street Week Ahead: Gap between vaccine hopes and pandemic reality poses market hazard

11/20/2020 | 11:34am EDT
FILE PHOTO: A street sign for Wall Street is seen outside the New York Stock Exchange in Manhattan, New York City

NEW YORK (Reuters) - As winter approaches, U.S. equity investors are weighing brightening prospects for a COVID-19 vaccine against a resurgence of the pandemic across the United States.

Several market strategists have predicted significant gains in U.S. stocks in 2021, as long as Congress passes further fiscal stimulus and a vaccine becomes widely available in the first half. But the path for stocks could be bumpy while investors await those developments, they said.

Over the past few weeks, investors had largely looked past immediate risks from the pandemic. The benchmark S&P 500 index recently soared to record highs on evidence of high efficacy rates in two experimental vaccines - from Moderna Inc and jointly from Pfizer Inc and BioNTech SE. Both vaccines could be ready for U.S. authorization and distribution within weeks, Health and Human Services Secretary Alex Azar has said.

Still, the pandemic remained an immediate threat as the number of U.S. deaths from the disease has climbed to 250,000. The S&P 500 fell more than 1% on Wednesday as New York City announced the closure of public schools.

Economic indicators including a rise in jobless claims last week signaled that the recovery may have stalled, reflecting the need for further fiscal stimulus, some investors said. Data from IHS Markit's flash purchasing managers' index and the Conference Board's consumer confidence survey are scheduled for release next week.

"We anticipate a vaccine becoming partially available this year, but that still leaves a gap," said Colin Moore, global chief investment officer at Columbia Threadneedle Investments.

Further signs the pandemic is growing more severe could stir volatility in U.S. stocks. The Cboe Volatility Index, known as Wall Street's "fear gauge," fell sharply after the U.S. presidential election but has leveled off and remains above its long-term average near 20. VIX futures also reflect elevated expectations for market gyrations throughout the first half of 2021.

Questions about more stimulus have fed volatility expectations, investors said. Two U.S. Senate runoff elections in Georgia scheduled for January could decide which political party controls that chamber and hence the scope of further pandemic relief.

"The big event risk in 2021 might be that's just completely off the table," said Derek Devens, senior portfolio manager of Neuberger Berman's options group, referring to further stimulus. "That would be a pretty negative event for the market."

Some strategists anticipate a bid to haven currencies as a hedge against market declines. TD Securities strategists wrote on Tuesday that they expect the dollar, which has weakened this month, to gain for a brief period in part due to "evolving COVID realities." Societe Generale has recommended options strategies that would benefit from a strengthening in the yen.

But overall, investors largely expect any further slide in U.S. stocks to be fleeting. Restrictions on mobility and economic activity in response to rising COVID-19 cases are likely to be more limited than in the spring, they said. New York City, for instance, has kept stores and restaurants open even as schools close.

Simply seeing a light at the end of the tunnel has helped limit investor anxiety, said David Lefkowitz, head of Americas equities at UBS Global Wealth Management. Even if a stimulus package does not materialize as expected, optimism about a vaccine could blunt any hit to U.S. stocks, in his view.

"There's a pretty clear line of sight to an improvement beginning after the first quarter," he said. "I don't think we're going to see a huge pullback because the market knows that this is a very temporary situation."

(Reporting by April Joyner; Editing by David Gregorio)

By April Joyner

ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
AUSTRALIAN DOLLAR / JAPANESE YEN (AUD/JPY) -1.08% 82.47 Delayed Quote.5.00%
BIONTECH SE -0.83% 212.42 Delayed Quote.160.57%
BRITISH POUND / JAPANESE YEN (GBP/JPY) -1.05% 152.156 Delayed Quote.8.99%
CANADIAN DOLLAR / JAPANESE YEN (CAD/JPY) -1.13% 88.349 Delayed Quote.10.17%
DJ INDUSTRIAL -1.58% 33290.08 Delayed Quote.10.51%
EURO / JAPANESE YEN (EUR/JPY) -0.54% 130.712 Delayed Quote.4.31%
JAPANESE YEN / SWISS FRANC (JPY/CHF) 0.63% 0.8365 Delayed Quote.-3.03%
MODERNA, INC. -1.62% 199.19 Delayed Quote.90.67%
NASDAQ 100 -0.81% 14049.584838 Delayed Quote.9.01%
NASDAQ COMP. -0.92% 14030.375849 Delayed Quote.8.86%
NATIONAL AUSTRALIA BANK LIMITED -0.52% 26.87 End-of-day quote.18.89%
NEW ZEALAND DOLLAR / JAPANESE YEN (NZD/JPY) -1.25% 76.417 Delayed Quote.4.41%
PFIZER, INC. -1.70% 38.81 Delayed Quote.5.43%
S&P 500 -1.31% 4166.45 Delayed Quote.10.93%
SOCIÉTÉ GÉNÉRALE SOCIÉTÉ ANONYME -3.40% 25.01 Real-time Quote.46.93%
UBS GROUP AG -2.02% 14.34 Delayed Quote.15.00%
US DOLLAR / JAPANESE YEN (USD/JPY) -0.16% 110.15 Delayed Quote.6.92%
06/18NATIONAL AUSTRALIA BANKá : Settles US Class Action Suit
06/17NATIONAL AUSTRALIA BANKá : Australia's NAB to settle U.S. bank bill swap rate cl..
06/17SHANGHAI STOCK EXCHANGE B SHARES IND : China's Consumption Lags in Economic Reco..
06/17Nasdaq closes up on tech stocks strength, as hawkish Fed limits S&P
06/17SHANGHAI STOCK EXCHANGE B SHARES IND : China's Economic Growth Slows as Low Base..
06/15S&P/ASX 200á : Reserve Bank of Australia Meeting Minutes Indicate Policy Adjustm..
06/11VIRUS TO VIRUS : pandemic to cyber threatá:Mike Dolan
06/11Australia shares rise for fourth week as U.S. inflation worries cool
06/09NAB Upgrades Its Macroeconomic Forecasts on Australia, Central Bank
06/09Australian shares end lower as banks, Woolworths drag
More news
Sales 2021 17 068 M 12 768 M 12 768 M
Net income 2021 6 006 M 4 493 M 4 493 M
Net Debt 2021 - - -
P/E ratio 2021 15,1x
Yield 2021 4,48%
Capitalization 88 468 M 66 219 M 66 181 M
Capi. / Sales 2021 5,18x
Capi. / Sales 2022 5,07x
Nbr of Employees 31 696
Free-Float 99,5%
Duration : Period :
National Australia Bank Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 27,23 AUD
Last Close Price 26,87 AUD
Spread / Highest target 13,5%
Spread / Average Target 1,34%
Spread / Lowest Target -8,82%
EPS Revisions
Managers and Directors
Ross Maxwell McEwan Group CEO, Managing Director & Director
Gary A. Lennon Group Chief Financial Officer
Philip Wayne Chronican Chairman
Patrick C. Wright Chief Technology Officer
Leslie Durno Matheson Chief Operating Officer